(secondQuint)A Safety and Efficacy Study to Evaluate AMG 334 in Migraine Prevention.

 This is a Phase 2, randomized, double-blind, placebo-controlled study in subjects with episodic migraine.

 The study is designed to evaluate if treatment with AMG 334 once a month for 6 months compared with placebo is effective in reducing the mean monthly migraine days.

 Additionally, this study will continue to evaluate the efficacy and safety of AMG 334 during the open label treatment phase where subjects will continue to receive active treatment monthly.

.

 A Safety and Efficacy Study to Evaluate AMG 334 in Migraine Prevention@highlight

Randomized, double-blind, placebo-controlled, parallel-group, multicenter study followed by an open-label treatment phase.

 To evaluate the effect of AMG 334 compared to placebo on the change from baseline in monthly migraine days.

